MannKind | MNKD - Cash And Equivalent


MannKind reported $52.83M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Adma Biologics USD 138.15M 50.52M Mar/2026
BioCryst Pharmaceuticals USD 171.59M 164.32M Mar/2026
Eli Lilly USD 5.28B 1.99B Mar/2026
Halozyme Therapeutics USD 309.75M 175.93M Mar/2026
Insmed USD 582.19M 71.74M Mar/2026
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
MacroGenics USD 66.52M 9.3M Mar/2026
MannKind USD 52.83M 22.05M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Novavax USD 228.36M 12.27M Mar/2026
Novo Nordisk DKK 38.94B 24.15B Mar/2025
Pfizer USD 1.7B 561M Mar/2026
Sanofi EUR 7.66B 1.25B Dec/2025
Xencor USD 14.17M 39.9M Mar/2026